原发部位不明腺癌

Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer. 2004;100:1776-1785.

• 全文
• 摘要

Pavlidis N, Briasoulis E, Hainsworth J, et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39:1990-2005.

• 摘要

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: occult primary (cancer of unknown primary). http://www.nccn.org/ (last accessed 15 May 2016).

• 全文

Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11:3766-3772.

• 全文
• 摘要

Diggs CH. Cancer of unknown primary site. Deciding how far to carry evaluation. Postgrad Med. 1989;86:186-191.

• 摘要

Greco FA, Vaughn WK, Hainsworth JD. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Intern Med. 1986;104:547-553.

• 摘要

Culine S, Lortholary A, Voigt JJ, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study - trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol. 2003;21:3479-3482.

• 摘要

Abbruzzese JL, Abbruzzese MC, Hess KR, et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994;12:1272-1280.

• 摘要

1.  Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer. 2004;100:1776-1785.

• 全文
• 摘要

2.  Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.

• 全文
• 摘要

3.  Muir C. Cancer of unknown primary site. Cancer. 1995;75:353-356.

• 摘要

4.  Coates M, Armstrong B. Cancer in New South Wales. Incidence and mortality 1994. Sydney: NSW Cancer Council; 1997.

5.  Parkin DM, Muir CS. Cancer incidence in five continents. Comparability and quality of data. IARC Sci Publ. 1992;120:45-173.

• 摘要

6.  Neumann G. The impact of cancer with unspecified site. Off Gesundheitswes. 1988;50:13-19.

7.  Naresh KN. Do metastatic tumours from an unknown primary reflect angiogenic incompetence of the tumour at the primary site?-a hypothesis. Med Hypotheses. 2002;59:357-360.

• 摘要

8.  Van't Veer LJ, Weigelt B. Road map to metastasis. Nat Med. 2003;9:999-1000.

• 摘要

9.  Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3:537-549.

• 摘要

10.  Hedley DW, Leary JA, Kirsten F. Metastatic adenocarcinoma of unknown primary site: abnormalities of cellular DNA content and survival. Eur J Cancer Clin Oncol. 1985;21:185-189.

• 摘要

11.  Pavlidis N, Briasoulis E, Hainsworth J, et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39:1990-2005.

• 摘要

12.  Su AI, Welsh JB, Sapinoso LM, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res. 2001;61:7388-7393.

• 全文
• 摘要

13.  Leader M, Patel J, Makin C, et al. An analysis of the sensitivity and specificity of the cytokeratin marker CAM 5.2 for epithelial tumours. Results of a study of 203 sarcomas, 50 carcinomas and 28 malignant melanomas. Histopathology. 1986;10:1315-1324.

• 摘要

14.  National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: occult primary (cancer of unknown primary). http://www.nccn.org/ (last accessed 15 May 2016).

• 全文

15.  Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11:3766-3772.

• 全文
• 摘要

16.  Anderson GG, Weiss LM. Determining tissue of origin for metastatic cancers: meta-analysis and literature review of immunohistochemistry performance. Appl Immunohistochem Mol Morphol. 2010;18:3-8.

• 摘要

17.  Pentheroudakis G, Greco FA, Pavlidis N. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review. Cancer Treat Rev. 2009;35:221-227.

• 摘要

18.  Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer. 2007;43:2026-2036.

• 摘要

19.  Diggs CH. Cancer of unknown primary site. Deciding how far to carry evaluation. Postgrad Med. 1989;86:186-191.

• 摘要

20.  Latief KH, White CS, Protopapas Z, et al. Search for a primary lung neoplasm in patients with brain metastasis: is the chest radiograph sufficient? AJR Am J Roentgenol. 1997;168:1339-1344.

• 全文
• 摘要

21.  Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol. 2009;19:731-744.

• 全文
• 摘要

22.  Pelosi E, Pennone M, Deandreis D, et al. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Q J Nucl Med Mol Imaging. 2006;50:15-22.

• 摘要

23.  Sève P, Billotey C, Broussolle C, et al. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer. 2007;109:292-299.

• 全文
• 摘要

24.  Monzon FA, Koen TJ. Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin. Arch Pathol Lab Med. 2010;134:216-224.

• 全文
• 摘要

25.  Bender RA, Erlander MG. Molecular classification of unknown primary cancer. Semin Oncol. 2009;36:38-43.

• 摘要

26.  U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151:716-726.

• 摘要

27.  Berg WA, Gutierrez L, NessAiver MS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. 2004;233:830-849.

• 全文
• 摘要

28.  Kupesic S, Plavsic BM. Early ovarian cancer: 3-D power Doppler. Abdom Imaging. 2006;31:613-619.

• 摘要

29.  Della-Fiorentina SA, Jaworski RC, Crandon AJ, et al. Primary peritoneal carcinoma: a treatable subset of patients with adenocarcinoma of unknown primary. Aust N Z J Surg. 1996;66:124-125.

• 摘要

30.  Regelink G, Brouwer J, de Bree R, et al. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur J Nucl Med Mol Imaging. 2002;29:1024-1030.

• 摘要

31.  Wei S, Said-Al-Naief N, Hameed O. Estrogen and progesterone receptor expression is not always specific for mammary and gynecologic carcinomas: a tissue microarray and pooled literature review study. Appl Immunohistochem Mol Morphol. 2009;17:393-402.

• 摘要

32.  Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol. 2005;48:386-399.

• 摘要

33.  Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.

• 摘要

34.  Amela EY, Lauridant-Philippin G, Cousin S, et al. Management of "unfavourable" carcinoma of unknown primary site: synthesis of recent literature. Crit Rev Oncol Hematol. 2012;84:213-223.

• 全文
• 摘要

35.  Greco FA, Vaughn WK, Hainsworth JD. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Intern Med. 1986;104:547-553.

• 摘要

36.  Sporn JR, Greenberg BR. Empirical chemotherapy for adenocarcinoma of unknown primary tumor site. Semin Oncol. 1993;20:261-267.

• 摘要

37.  Culine S, Lortholary A, Voigt JJ, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study - trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol. 2003;21:3479-3482.

• 摘要

38.  Dowell JE, Garrett AM, Shyr Y, et al. A randomized phase II trial in patients with carcinoma of an unknown primary site. Cancer. 2001;91:592-597.

• 全文
• 摘要

39.  Greco FA, Erland JB, Morrissey LH, et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol. 2000;11:211-215.

• 全文
• 摘要

40.  Golfinopoulos V, Pentheroudakis G, Salanti G, et al. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev. 2009;35:570-573.

• 摘要

41.  Rao G, Crispens M, Rothenberg ML. Intraperitoneal chemotherapy for ovarian cancer: overview and perspective. J Clin Oncol. 2007;25:2867-2872.

• 摘要

42.  Hainsworth JD, Johnson DH, Greco FA. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. Ann Intern Med. 1988;109:364-371.

• 摘要

43.  Ricci S, Antonuzzo A, Galli L, et al. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol. 2000;11:1127-1130.

• 全文
• 摘要

44.  Greco FA, Burris HA 3rd, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol. 2002;20:1651-1656.

• 摘要

45.  Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358:1663-1671. [Errata in: N Engl J Med. 2008;359:106; N Engl J Med. 2009;360:1685.]

• 全文
• 摘要

46.  Hainsworth JD, Spigel DR, Farley C, et al. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol. 2007;25:1747-1752.

• 全文
• 摘要

47.  van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, et al. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer. 2002;38:409-413.

• 摘要

48.  Abbruzzese JL, Abbruzzese MC, Hess KR, et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994;12:1272-1280.

• 摘要

49.  Hayes DF. Prognostic and predictive factors revisited. Breast. 2005;14:493-499.

• 摘要

50.  Kennedy AW, Markman M, Webster KD, et al. Experience with platinum-paclitaxel chemotherapy in the initial management of papillary serous carcinoma of the peritoneum. Gynecol Oncol. 1998;71:288-290.

• 摘要

51.  Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer. 2006;42:1031-1039.

• 摘要